The ideal use of a surrogate marker in cancer is to support the accelerated approval of a new therapeutic more rapidly than could be accomplished using hard clinical end points. Although Aeterna Laboratories Inc. is using clinical end points in two pivotal trials of its Neovastat oral angiogenesis inhibitor, it has decided that in a third cancer, a surrogate marker makes more sense.

Clinical end points are being used in two ongoing Phase III trials of Neovastat (AE-941), in non-small cell lung cancer (NSCLC) and in renal cell carcinoma (RCC). A 760-patient North American Phase III